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Sunday, June 12, 2016 
16:00 - 18:30 Conference check-in 
18:30 - 19:30 Opening Keynote 
 Vaccines: Reaching for higher branches after the low hanging fruit has been 
picked 
Michael Kurilla, National Institute of Allergy and Infectious Diseases (NIAID), USA 
 
19:30 - 21:00 
Dinner 
 
 
 
NOTES 
 
 Technical Sessions will be held in Sala Grande Real. 
 
 Poster Sessions will be held in Grande Real Foyer. 
 
 Most meals will be in the Restaurante do Real.  Changes will be announced.  
 
 The conference banquet on Thursday will be held in the Restaurante Santa Eulalia. 
 
 Audiotaping, videotaping and photography of presentations are prohibited. 
 
 Speakers – Please leave at least 5 minutes for questions and discussion. 
 
 Please do not smoke at any conference functions. 
 
 Turn your cellular telephones to vibrate or off during technical sessions. 
 
 After the conference, ECI will send an updated participant list to all participants.  Please check 
your listing now and if it needs updating, you may correct it at any time by logging into your ECI 
account.  
 
 Please do not smoke at any conference functions. 
 
 Please write your name in the front of this program booklet so it can be returned if misplaced. 
  
Monday, June 13, 2016 
07:30 - 08:30 Breakfast buffet 
08:30 – 10:30 Session I: Break Through Developments in Vaccinology 
Chairs: Florian Krammer, The Mount Sinai Hospital, USA, and Hari Pujar, Moderna 
Therapeutics, USA 
 
08:30 – 09:00 A universal influenza virus vaccine candidate confers protection against 
pandemic H1N1 infection in ferrets 
Raffael Nachbagauer, Icahn School of Medicine at Mount Sinai, USA  
09:00 – 09:30 Single-cell analysis of Influenza A virus-infected cells for the optimization of cell 
culture-based vaccine production 
Sascha Young Kupke, Max Planck Institute for Dynamics of Complex Technical 
Systems, Germany 
09:30 – 10:00 Development of Typhax, a Salmonella Typhi Vi polysaccharide protein capsular 
matrix vaccine 
Kevin P. Killeen, Matrivax R&D Corp, USA 
10:00 – 10:30 Quantitative, molecular-level analysis of the serum antibody repertoire reveals 
unanticipated features of the response to seasonal influenza vaccination  
Jiwon Lee, The University of Texas at Austin, USA  
 
10:30 - 11:00 Coffee break (Sponsored by Applikon Biotechnology B.V.) 
11:00 – 13:00 Session II: Issues and Case Studies in Process Development 
Chairs: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, 
India 
 
11:00 – 11:24 Upstream and downstream process development of a Vero cell-based yellow 
fever vaccine 
Leda R. Castilho, Federal University of Rio de Janeiro (UFRJ), Brazil 
11:24 – 11:48 Fast-track lentiviral vector upstream process development: Leveraging high-
throughput process monitoring, single-use bioreactor scalability 
Nicolas Sève, Sanofi Pasteur, France 
11:48 – 12:12 Hollow fiber-based high-cell-density and two-stage bioreactor continuous 
cultivation: Options and limits towards process intensification for virus 
production 
Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
12:12 – 12:36 A live attenuated RSV vaccine, process development studies 
Yvonne E. Thomassen, Intravacc, Netherlands 
12:36 – 13:00 Genetic engineering of vaccine manufacturing cell lines enhances poliovirus 
and enterovirus 71 production 
Jon M. Karpilow, Proventus Bio, USA 
13:00 - 14:00 Lunch 
Monday, June 13, 2016 (continued) 
14:00 - 15:30 Workshop I: Are regulatory hurdles limiting vaccine manufacturing innovation?  
Facilitators: Katey Owen, The Bill and Melinda Gates Foundation, USA and David 
Robinson, Robinson Vaccines and Biologics LLC, USA 
15:30 - 16:00 Ad hoc discussions/networking time 
16:00 - 18:00 Session III: Formulating and Delivering Vaccines 
Chair: David Volkin, University of Kansas, USA 
 
16:00 – 16:30 Adjuvants in preclinical and clinical development: The do and don’t 
Nathalie Garçon, BIOASTER Technology Research Institute, France 
16:30 – 17:00 Combining DOE with an empirical approach to improve vaccine formulation 
development 
Jill Livengood, Takeda, USA 
17:00 – 17:30 Development of a thermostable ID93 + GLA-SE vaccine using a design of 
experiments (DOE) approach 
Ryan M. Kramer, Infectious Disease Research Institute (non-profit), USA 
17:30 – 18:00 Controlled, pulsatile release of thermostabilized inactivated polio vaccine from 
PLGA-based microspheres 
Stephany Y. Tzeng, Massachusetts Institute of Technology, USA 
18:00 - 20:00 Dinner 
20:00 - 22:00 Poster Session I with Social Hour 
Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico, Antonio 
Roldao, IBET, Portugal 
 
  
Tuesday, June 14, 2016 
07:30 - 08:30 Breakfast buffet 
08:30 – 10:30 Session IV: Therapeutic Vaccines 
Chairs: Jean Boyer, Inovio, USA, and Tarit Mukhopadhyay, University College 
London, United Kingdom 
 
08:30 – 09:00  Current technologies for advancing HIV vaccines 
Vadim Tsvetnitsky, IAVI, USA 
09:00 – 09:30 Applications of DNA vaccine technology towards difficult immune targets 
David Weiner, University of Pennsylvania, USA 
(Lecture sponsored by Vaccine Journal (Elsevier)) 
 
09:30 – 10:00 Advancing the mRNA therapeutics platforms for vaccines 
Hari Pujar, Moderna Therapeutics, USA 
 
10:00 – 10:30  Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate 
cancer 
Helen Cho, Pfizer, USA 
 
10:30 - 11:00 Coffee break (Sponsored by GE Healthcare) 
11:00 - 12:00 Keynote lecture 
Development of immunotherapeutic immunizations for virus infections and 
cancer 
Ian Frazer, University of Queensland, Australia 
12:00 - 13:30 Workshop II: Academy-Industry Interactions for Advancing in Vaccine 
Development  
Facilitators: Alex Xenopoulos, EMD Millipore, USA and Manuel JT Carrondo, IBET, 
Portugal 
14:00 - 19:30 Pick up boxed lunch 
 Boat excursion and guided tour of Faro 
19:30 Dinner on your own 
 
 
 
  
Wednesday, June 15, 2016 
07:30 - 08:30 Breakfast buffet 
08:30 - 10:30 Session V: Getting Vaccines to the Market: Case studies 
Chair: Rebecca Sheets, Grimalkin Partners, USA and Danilo Casimiro, Aeras, USA 
 
08:30 – 09:00 RSV vaccines for the Young and the old 
Albert E. Price, MedImmune, USA 
09:00 – 09:30 Development, manufacturing, and supply of MSD’s Ebola vaccine 
Jeffrey T. Blue, Merck Sharp & Dohme Corp.,  USA 
9:30 – 10:00 Third generation vaccine for world eradication of poliomyelitis 
Emilie Rodrigues, Intravacc, Netherlands 
10:00 – 10:30 Improving global human health through norovirus virus-like particle 
manufacturing 
Scot Shepard, Takeda Vaccines, USA 
 
10:30 - 11:00 Coffee break (Sponsored by Medimmune) 
11:00 - 12:00 Keynote Lecture  
How is vaccine R&D pipeline strategy going to evolve for pharm industry…? 
Johan Van Hoof, Janssen Research and Development, Belgium 
12:00 - 13:00 Ad hoc discussions / networking 
13:00 - 14:00 Lunch 
14:00 - 15:30 Workshop III: Vaccine Design and Evaluation - The iVAX Toolkit  
Facilitator: Frances Terry, EpiVax, USA 
15:30 - 17:00 Ad hoc discussions / networking 
17:00 – 18:00 Session II: Issues and Case Studies in Process Development (continued) 
Chair: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, 
India  
 
17:00 – 17:20 Challenges in the development and scale-up of a purification process for an 
attenuated live virus vaccine candidate 
Matthew Woodling, Merck & Co., Inc., Pennsylvania, USA 
17:20 – 17:40 Insect cells platforms for fast production of Pseudo-Typed VLPs for drug and 
vaccine development 
Antonio Roldao, IBET, Portugal 
17:40 – 18:00 Determining whether adsorption state is a critical attribute in aluminum 
adjuvanted vaccines 
Garry Morefield, VaxForm, USA 
18:00 - 20:00 Dinner 
Wednesday, June 15, 2016 (continued) 
20:00 - 22:00 Poster session II and Social Hour  
Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico, 
Antonio Roldao, IBET, Portugal 
 
  
Thursday, June 16, 2016 
07:30 - 08:30 Breakfast buffet 
08:30 – 10:30 Session VI: Vaccine Characterization and Analytics 
Chairs: Linda Lua, University of Queensland, Australia, and Indresh Srivastava, 
Protein Sciences, USA 
 
08:30 – 09:00 Analytical characterization of human Cytomegalovirus vaccine and vaccine 
induced humoral responses 
Sha Ha, Merck & Co., Inc., Pennsylvania, USA 
 
09:00 – 09:30 Multi-tasking an inactivated influenza vaccine to provide rapid innate immune-
system mediated protection and subsequent long-term adaptive immunity 
against influenza and secondary pneumococcal infections 
Brendon Y. Chua, The University of Melbourne, Australia 
09:30 – 10:00 Correlations of antibody response phenotype to genotype revealed by 
molecular amplification fingerprinting 
Sai Reddy, ETH Zurich, Switzerland 
10:00 – 10:30 Immune engineering enhances H7N9 vaccine immunogenicity by regulatory T 
cell epitope deletion in hemagglutinin 
Annie De Groot, EpiVax, Inc., Institute for Immunology and Informatics, University of 
Rhode Island, USA 
10:30 - 11:00 Coffee break (Sponsored by Pfizer) 
11:00 – 13:00 Session VII: One World, One Health 
Chairs: Jean-Christophe Audonnet, Merial, France, Juan Garza, UNAM,  
Ab Osterhaus, University of Veterinary Medicine Hannover, Germany  
 
11:00 – 11:30 Vaccination as a tool to reduce antimicrobial resistance worldwide 
Bernard Vallat, OIE, France 
 
11:30 – 11:55 Structural-based designed modular capsomere comprising HA1 as low-cost 
poultry influenza vaccine 
Jarurin Waneesorn, The University of Queensland, Australia 
 
11:55 – 12:20 Development of a vaccine based on recombinant subunit proteins to protect 
humans and animals against filovirus disease 
Axel T. Lehrer, University of Hawaii, USA 
 
12:20 – 12:40 How to deliver new vaccines under very short timelines: The ZAPI project 
Jean Christophe Audonnet, Merial, France 
 
12:40 – 13:00 From virus discovery to intervention 
Ab Osterhaus, University of Veterinary Medicine Hannover, Germany 
 
13:00 - 14:00 Poster session I with Grazing Lunch  
Chairs: Valerie Mermall, Protein Sciences Corporation, USA, Ruth Pastor, UNAM, 
Mexico, Antonio Roldao, IBET, Portugal 
 
Thursday, June 16, 2016 (continued) 
14:00 - 15:00 Poster session II with Grazing Lunch  
Chairs: Valerie Mermall, Protein Sciences Corporation, USA, Ruth Pastor, UNAM, 
Mexico, Antonio Roldao, IBET, Portugal 
15:00 - 16:00 Ad hoc discussions / Networking 
16:00 - 19:00 Session VIII: New Challenges and Technologies in Vaccine Development 
Chairs: Albert Price, MedImmune, USA and Odile Leroy, European Vaccine Initiative, 
Germany 
 
16:00 – 16:25 Systems biology and single cell approaches to study human immune 
responses to vaccination 
John Tsang, NIAID, USA 
16:25 – 16:50 Structure-based Vaccine Design: Lessons from RSV F 
Jason McLellan, Geisel School of Medicine at Dartmouth, USA 
16:50 – 17:15 Induction of antigen-specific immune tolerance with synthetic nanoparticle 
vaccines 
Petr Ilynskii, Selecta Biosciences, USA 
17:15 – 17:45 Universal and in-process analytical tool for Influenza quantification using a 
label-free technology 
Sofia Carvalho, iBET/ITQB, Portugal 
17:45 - 18:10 Coffee break 
18:10 – 18:35 Applications of high-throughput single B-cell sequencing to accelerate rational 
vaccine design 
Brandon J. DeKosky, Vaccine Research Center / NIAID, USA 
18:35 – 19:00 Plant-based technologies to enable rapid response to Ebola outbreak 
Jerzy Karczewski & Vidadi Yusibov, Fraunhofer USA, USA 
19:00 - 20:00 Closing Keynote  
 
Katey Owen, Deputy Director, Vaccines Development CMC, The Bill & Melinda 
Gates Foundation, USA 
20:00 - 22:00 Conference Banquet 
 
  
Friday, June 17, 2016 
07:30 - 09:00 Breakfast Buffet  
 Departures 
 
  
Poster Presentation List 
 
1.  Influenza vaccine production using cell culture with microcarriers 
Alex Xenopoulos, EMD Millipore, USA 
 
2.  Evaluation and scale-up of single-use bioreactors for the production and harvesting of 
a hepatitis C vaccine candidate 
Alex Xenopoulos, EMD Millipore, USA 
 
3.  Computational fluid dynamics modeling for HPV fermentation bioreactors 
Tracie Spangler, Merck, USA 
 
4.  Development of a stabilized trimer pre-fusion RSV F recombinant viral glycoprotein 
vaccine 
Richard M. Schwartz, NIAID, NIH, USA 
 
5.  Optimization of sulfated cellulose membrane adsorbers for the purification of 
influenza virus 
A. Raquel Fortuna, Max-Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
6.  Purification of cell culture-derived influenza virus via continuous chromatography 
Laura M. Fischer, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
7.  Optimization and scale-up of cell culture and purification processes for production of 
an adenovirus-vectored tuberculosis vaccine candidate 
Aziza Manceur, National Research Council, Canada 
 
8.  Pan-HA antibodies for influenza detection and quantification 
Aziza Manceur, National Research Council, Canada 
 
9.  High titer production of HIV-1 virus-like particles by CAP-T cells 
Sonia Gutiérrez-Granados, Universitat Autònoma de Barcelona, Spain 
 
10.  Characterization of HA and NA-containing VLPs produced in suspension cultures of 
HEK 293 cells. 
Amine Kamen, McGill University, Canada 
 
11.  Novel avian DuckCeltTM-T17 cell line for production of viral vaccines : application to 
influenza viruses production. 
Emma Petiot, Université Claude Bernard Lyon 1 - CIRI, France 
 
12.  Pseudo-affinity purification and formulation of a cell-culture derived whole influenza 
virus vaccine using magnetic sulfated cellulose particles 
Michael Martin Pieler, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
13.  Trumenba: A case study for development of a drug substance manufacturing process 
through commercialization 
Khurram Sunasara, Pfizer, USA 
 
14.  A stabilized subunit vaccine for ebola virus 
Keith Chappell,  University of Queenslandcular Bioscience, Australia 
 
15.  Improved seed train strategy applied to PER.C6® cells for manufacturing readiness in 
vaccines production 
Piergiuseppe Nestola, Janssen Vaccines AG, Switzerland 
 
16.  History and development of a liquid formulation for adenoviral vaccines 
Lara Babich, Janssen Infectious Diseases & Vaccines, Netherlands 
 
17.  Tetraspanins displayed in retrovirus-derived virus-like particles and their impact in 
vaccine development 
Hugo R. Soares, iBET, Portugal 
 
18.  A modular approach for efficient production of multi-HA Influenza VLP-based vaccines 
António Roldão, Instituto de Biologia Experimental e Tecnológica (iBet), Portugal 
 
19.  Improving downstream processing of enveloped virus-like particles with multi-column 
chromatography 
Ricardo Silva, iBET, Portugal 
 
20.  A click chemistry strategy to specifically monitor and improve purification of Influenza 
virus-like particles 
Sofia Carvalho, iBET/ITQB, Portugal 
 
21.  Enveloped virus-like particles purification using an all-filtration technology platform 
Sofia Carvalho, IBET/ITQB-UNL, Portugal 
 
22.  The papaya mosaic virus (PapMV) nanoparticles; a promising tool in vaccine 
development. 
Denis Leclerc, U Laval, Canada 
 
23.  Novel pulsatile-release microparticles for single-injection vaccination 
Stephany Y. Tzeng, Massachusetts Institute of Technology, USA 
 
24.  Structurally confined influenza subunit vaccines in the prefusion conformation elicit a 
potent neutralizing antibody response 
Daniel Watterson, University of Queensland, Australia 
 
25.  Vaccination with recombinant neuraminidase protects against influenza virus 
infection in mice 
Teddy John Wohlbold, Icahn School of Medicine at Mount Sinai, USA 
 
26.  Residual DNA analysis in influenza vaccine processing 
Camilla Estmer Nilsson, GE Healthcare, Sweden 
 
27.  Study of rabies VLPs expression in BHK-21 cell line for vaccine applications 
Claudio Prieto, Universidad Nacional Del Litoral, Argentina 
 
28.  Expression of rabies VLPs in adherence and suspension conditions: a flexible 
platform for rabies vaccine production 
Diego Fontana, Universidad Nacional Del Litoral, Argentina 
 
29.  Process economy effects of modernizations in vaccine purification 
Mia Bennemo, GE Healthcare Life Sciences, Sweden 
 
30.  Propagation of influenza and MVA virus in cascades of continuous stirred tank 
bioreactors: challenging the "Von Magnus effect" 
Felipe Tapia, Max Planck Institute Magdeburg, Germany 
31.  Intensification of MVA and influenza virus production through high-cell-density 
cultivation approaches 
Daniel Vazquez, Max Planck Institute, Magdeburg, Germany 
 
32.  Production of a Nanoplasmid™ with a large gene insert using the HyperGRO™ 
fermentation process 
Aaron Carnes, Nature Technology Corporation, USA 
 
33.  Virus-like particles adsorption in anion exchange chromatography media 
Patricia Pereira Aguilar, University of Natural Resources and Life Sciences Vienna (BOKU), 
Austria 
 
34.  Ready to use gamma irradiated microcarriers for virus production in single use 
bioreactor systems 
Gustaf Ahlén, GE Healthcare Biosciences, Sweden 
 
35.  Development of a versatile vaccination platform based on papaya mosaic virus 
(PapMV) nanoparticles 
Ariane Therien, Université Laval, Canada 
 
36.  Evaluation of producer cell lines for yellow fever virus production in up to 1 L 
bioreactor scale 
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
37.  Propagation of Brazilian Zika virus strains in static,  microcarrier-based and 
suspension cultures using BHK and Vero cells 
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, 
Germany 
 
38.  Electron microscopy as an emerging analytical tool for characterizing vaccines 
Anette Schneemann, NanoImaging Services Inc, USA 
 
39.  Optimizing scale-up of Vero cells cultured on microcarriers in serum-free medium for 
vaccine production 
Anna-Barbara Hachmann, Thermo Fisher Scientific, USA 
 
40.  Custom open polyethersulfone ultrafiltration membranes for vaccines 
Clifton Ngan, MilliporeSigma, USA 
 
41.  Highly cross-conserved burkholderia T cell epitopes generate effector T cell 
responses in vitro 
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